慢性骨髄性白血病治療法の世界市場2019-2023

【英語タイトル】Chronic Myelogenous Leukemia Therapeutics Market by Product and Geography - Global Forecast and Analysis 2019-2023

Technavioが出版した調査資料(IRTNTR31940)・商品コード:IRTNTR31940
・発行会社(調査会社):Technavio
・発行日:2019年8月28日
・ページ数:157
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル、アジア太平洋、ヨーロッパ、北米、その他
・産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥267,500見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥321,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥428,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
Technavio社の本調査レポートでは、慢性骨髄性白血病治療法の世界市場について調べ、慢性骨髄性白血病治療法の市場状況、市場規模、市場予測、市場環境、顧客状況、市場動向、関連企業情報などをまとめました。また、慢性骨髄性白血病治療法の市場規模をセグメンテーション別(製品別(標的療法、化学療法、免疫療法)、)と地域別(グローバル、アジア太平洋、ヨーロッパ、北米、その他)に分けて算出しました。Technavio社は慢性骨髄性白血病治療法の世界市場規模が2019-2023期間中に年平均6%成長すると予測しています。
・サマリー
・レポートの範囲
・慢性骨髄性白血病治療法の市場状況
・慢性骨髄性白血病治療法の市場規模
・慢性骨髄性白血病治療法の市場予測
・慢性骨髄性白血病治療法の世界環境:ファイブフォース分析
・市場セグメンテーション:製品別(標的療法、化学療法、免疫療法)
・慢性骨髄性白血病治療法の顧客状況
・主要地域別市場規模:グローバル、アジア太平洋、ヨーロッパ、北米、その他
・市場動向・成長要因・課題
・関連企業状況・企業分析
 ...
【レポートの概要】

Global Chronic Myelogenous Leukemia (CML) Therapeutics Market: About this market
Technavio’s chronic myelogenous leukemia (CML) therapeutics market analysis considers sales from targeted therapy, chemotherapy, and immunotherapy. Our analysis also considers the sales of chronic myelogenous leukemia (CML) therapeutics in Asia, Europe, North America, and ROW. In 2018, the targeted therapy segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as increasing number of approvals for orphan drug destinations will play a significant role in the targeted therapy segment to maintain its market position. Also, our global chronic myelogenous leukemia (CML) therapeutics market report looks at factors such as advent of novel therapies, patient assistance programs for TKIs, and strategic alliance. However, patent expiration of TKIs, availability of substitutes, and late diagnosis of CML may hamper the growth of the chronic myelogenous leukemia (CML) therapeutics industry over the forecast period.

Global Chronic Myelogenous Leukemia (CML) Therapeutics Market: Overview

Strategic alliances
The global CML therapeutics market has witnessed multiple strategic alliances in recent years. Vendors in the global CML therapeutics market are also collaborating to expand their distribution networks and overcome challenges associated with the high cost of R&D of CML therapeutics. These alliances include license agreement among educational institutions, support groups, pharma, and diagnostic companies. Furthermore, the collaborations with foundations and support groups also contribute to market growth by increasing patient adherence by reducing the cost burden. In March 2019, BMS in collaboration with The Max Foundation to assist cancer patients who are unable to access the treatment. This will lead to the expansion of the global chronic myelogenous leukemia (CML) therapeutics market at a CAGR of almost 6% during the forecast period.

Development of diagnostic tests and predictive markers
The companies that develop diagnostic methods are conducting research on developing new diagnostic testing methods that could help in an early detection of CML for treating diseases effectively using therapeutics. These developments include diagnostic kit in oncology which can effectively monitor the molecular response of the indication at an early stage. This development is expected to have a positive impact on the overall market growth.
For the detailed list of factors that will drive the global chronic myelogenous leukemia (CML) therapeutics market during the forecast period 2019-2023, click here.

Competitive Landscape
With the presence of several major players, the global chronic myelogenous leukemia (CML) therapeutics market is fragmented. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading chronic myelogenous leukemia (CML) therapeutics manufacturers, that include Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Mylan NV, Novartis AG, Otsuka Holdings Co. Ltd., Pfizer Inc., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd.

Also, the chronic myelogenous leukemia (CML) therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Targeted therapy – Market size and forecast 2018-2023
• Chemotherapy – Market size and forecast 2018-2023
• Immunotherapy – Market size and forecast 2018-2023
• Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2018-2023
• Europe – Market size and forecast 2018-2023
• Asia – Market size and forecast 2018-2023
• ROW – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 09: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 10: MARKET TRENDS
• Emergence of pipeline molecules
• Development of diagnostic tests and predictive markers
• Increasing research in regenerative medicines
PART 11: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 12: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Co.
• F. Hoffmann-La Roche Ltd.
• Merck & Co. Inc.
• Mylan NV
• Novartis AG
• Otsuka Holdings Co. Ltd.
• Pfizer Inc.
• Takeda Pharmaceutical Co. Ltd.
• Teva Pharmaceutical Industries Ltd.
PART 13: APPENDIX
• Research methodology
• List of abbreviations
• Definition of market positioning of vendors
PART 14: EXPLORE TECHNAVIO

Exhibit 01: Vendors: Key offerings
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2018
Exhibit 18: Product – Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Targeted therapy – Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Targeted therapy – Year-over-year growth 2019-2023 (%)
Exhibit 22: Chemotherapy – Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Chemotherapy – Year-over-year growth 2019-2023 (%)
Exhibit 24: Immunotherapy – Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Immunotherapy – Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by product
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: North America – Market size and forecast 2018-2023 ($ millions)
Exhibit 31: North America – Year-over-year growth 2019-2023 (%)
Exhibit 32: Top 3 countries in North America
Exhibit 33: Europe – Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Europe – Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in Europe
Exhibit 36: Asia – Market size and forecast 2018-2023 ($ millions)
Exhibit 37: Asia – Year-over-year growth 2019-2023 (%)
Exhibit 38: Top 3 countries in Asia
Exhibit 39: ROW – Market size and forecast 2018-2023 ($ millions)
Exhibit 40: ROW – Year-over-year growth 2019-2023 (%)
Exhibit 41: Top 3 countries in ROW
Exhibit 42: Key leading countries
Exhibit 43: Market opportunity
Exhibit 44: Impact of drivers and challenges
Exhibit 45: Vendor landscape
Exhibit 46: Landscape disruption
Exhibit 47: Vendors covered
Exhibit 48: Vendor classification
Exhibit 49: Market positioning of vendors
Exhibit 50: Boehringer Ingelheim International GmbH – Vendor overview
Exhibit 51: Boehringer Ingelheim International GmbH – Product segments
Exhibit 52: Boehringer Ingelheim International GmbH – Organizational developments
Exhibit 53: Boehringer Ingelheim International GmbH – Geographic focus
Exhibit 54: Boehringer Ingelheim International GmbH – Segment focus
Exhibit 55: Boehringer Ingelheim International GmbH – Key offerings
Exhibit 56: Boehringer Ingelheim International GmbH – Key customers
Exhibit 57: Bristol-Myers Squibb Co. – Vendor overview
Exhibit 58: Bristol-Myers Squibb Co. – Product segments
Exhibit 59: Bristol-Myers Squibb Co. – Organizational developments
Exhibit 60: Bristol-Myers Squibb Co. – Geographic focus
Exhibit 61: Bristol-Myers Squibb Co. – Key offerings
Exhibit 62: Bristol-Myers Squibb Co. – Key customers
Exhibit 63: F. Hoffmann-La Roche Ltd. – Vendor overview
Exhibit 64: F. Hoffmann-La Roche Ltd. – Product segments
Exhibit 65: F. Hoffmann-La Roche Ltd. – Organizational developments
Exhibit 66: F. Hoffmann-La Roche Ltd. – Geographic focus
Exhibit 67: F. Hoffmann-La Roche Ltd. – Segment focus
Exhibit 68: F. Hoffmann-La Roche Ltd. – Key offerings
Exhibit 69: F. Hoffmann-La Roche Ltd. – Key customers
Exhibit 70: Merck & Co. Inc. – Vendor overview
Exhibit 71: Merck & Co. Inc. – Product segments
Exhibit 72: Merck & Co. Inc. – Organizational developments
Exhibit 73: Merck & Co. Inc. – Geographic focus
Exhibit 74: Merck & Co. Inc. – Segment focus
Exhibit 75: Merck & Co. Inc. – Key offerings
Exhibit 76: Merck & Co. Inc. – Key customers
Exhibit 77: Mylan NV – Vendor overview
Exhibit 78: Mylan NV – Product segments
Exhibit 79: Mylan NV – Organizational developments
Exhibit 80: Mylan NV – Geographic focus
Exhibit 81: Mylan NV – Segment focus
Exhibit 82: Mylan NV – Key offerings
Exhibit 83: Mylan NV – Key customers
Exhibit 84: Novartis AG – Vendor overview
Exhibit 85: Novartis AG – Product segments
Exhibit 86: Novartis AG – Organizational developments
Exhibit 87: Novartis AG – Geographic focus
Exhibit 88: Novartis AG – Segment focus
Exhibit 89: Novartis AG – Key offerings
Exhibit 90: Novartis AG – Key customers
Exhibit 91: Otsuka Holdings Co. Ltd. – Vendor overview
Exhibit 92: Otsuka Holdings Co. Ltd. – Product segments
Exhibit 93: Otsuka Holdings Co. Ltd. – Organizational developments
Exhibit 94: Otsuka Holdings Co. Ltd. – Geographic focus
Exhibit 95: Otsuka Holdings Co. Ltd. – Segment focus
Exhibit 96: Otsuka Holdings Co. Ltd. – Key offerings
Exhibit 97: Otsuka Holdings Co. Ltd. – Key customers
Exhibit 98: Pfizer Inc. – Vendor overview
Exhibit 99: Pfizer Inc. – Product segments
Exhibit 100: Pfizer Inc. – Organizational developments
Exhibit 101: Pfizer Inc. – Geographic focus
Exhibit 102: Pfizer Inc. – Segment focus
Exhibit 103: Pfizer Inc. – Key offerings
Exhibit 104: Pfizer Inc. – Key customers
Exhibit 105: Takeda Pharmaceutical Co. Ltd. – Vendor overview
Exhibit 106: Takeda Pharmaceutical Co. Ltd. – Product segments
Exhibit 107: Takeda Pharmaceutical Co. Ltd. – Organizational developments
Exhibit 108: Takeda Pharmaceutical Co. Ltd. – Geographic focus
Exhibit 109: Takeda Pharmaceutical Co. Ltd. – Key offerings
Exhibit 110: Takeda Pharmaceutical Co. Ltd. – Key customers
Exhibit 111: Teva Pharmaceutical Industries Ltd. – Vendor overview
Exhibit 112: Teva Pharmaceutical Industries Ltd. – Product segments
Exhibit 113: Teva Pharmaceutical Industries Ltd. – Organizational developments
Exhibit 114: Teva Pharmaceutical Industries Ltd. – Segment focus
Exhibit 115 Teva Pharmaceutical Industries Ltd. – Key offerings
Exhibit 116: Teva Pharmaceutical Industries Ltd. – Key customers
Exhibit 117: Validation techniques employed for market sizing
Exhibit 118: Definition of market positioning of vendors



【掲載企業】

Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Mylan NV, Novartis AG, Otsuka Holdings Co. Ltd., Pfizer Inc., Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd.

★調査レポート[慢性骨髄性白血病治療法の世界市場2019-2023] (コード:IRTNTR31940)販売に関する免責事項を必ずご確認ください。
★調査レポート[慢性骨髄性白血病治療法の世界市場2019-2023]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆